Table 3 Patient characteristics
From: Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma
BC patients | 98 total |
Tumor samples—n (%) | 98 (100.0) |
Benigne samples—n (%) | 47 (100.0) |
Gender—n (%) | |
Female | 23 (23.5) |
Male | 75 (76.5) |
Age, years | |
Median (range) | 69 (32–84) |
pT-Stage—n (%) | |
2a | 15 (15.5) |
2b | 13 (13.6) |
3a | 22 (22.7) |
3b | 24 (24.7) |
4a | 17 (17.5) |
4b | 6 (6.2) |
Unknown | 1 |
Grading—n (%) | |
1 | 0 |
2 | 23 (23.5) |
3 | 75 (76.5) |
Concomitant CIS—n (%) | |
Yes | 28 (30.1) |
No | 65 (69.9) |
Unknown | 5 |
cN-Stage—n (%) | |
0 | 56 (59.5) |
1 | 23 (24.5) |
2 | 13 (13.7) |
3 | 2 (2.3) |
Unknown | 4 |
cM-Stage—n (%) | |
0 | 85 (90.4) |
1 | 9 (9.6) |
Unknown | 4 |
R-Stage—n (%) | |
0 | 80 (81.6) |
1 | 15 (15.3) |
2 | 3 (3.1) |